Written by Peter G. Traber, M.D. on September 2, 2015 In late June 2015, Galectin Therapeutics initiated a Phase 2 clinical trial (the NASH-CX trial) to evaluate the ability of...
Read More Successful Phase 1 Clinical Trial Supports Phase 2 Clinical Development Program
1 Comments , in Article
Written by Peter G. Traber, M.D. on August 24, 2015 Galectin Therapeutics completed and reported on a successful Phase 1 clinical trial in NASH patients with advanced fibrosis. In a...
Read More The Potential for Treatment of Liver Fibrosis With Galectin’s Drug Candidate GR-MD-02
0 Comments , in Article
Written by Peter G. Traber, M.D. on July 31, 2015 Liver fibrosis is scar formation in the liver which, when it reaches a large amount of scar tissue (called cirrhosis),...
Read More